Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HLA inhibitors(人类白细胞抗原抑制剂) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | United States | 28 Apr 2025 | |
Squamous non-small cell lung cancer | Preclinical | United States | 28 Apr 2025 | |
Triple Negative Breast Cancer | Preclinical | United States | 28 Apr 2025 |